Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experience

Autor: Robert N. Whistance, Sunil K. Ohri, Clifford W. Barlow, Apostolos Roubelakis, S. A. Livesey, Hunaid A. Vohra, Geoffrey Tsang, Andrew Burton
Rok vydání: 2012
Předmět:
Adult
Male
Reoperation
Pulmonary and Respiratory Medicine
Aortic valve
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Kaplan-Meier Estimate
Prosthesis Design
Risk Assessment
Ventricular Function
Left
Young Adult
Postoperative Complications
Valve replacement
Risk Factors
Mitral valve
E-Comment
medicine
Humans
Endocarditis
Hospital Mortality
Prosthetic Valve Thrombosis
Aged
Proportional Hazards Models
Retrospective Studies
Aged
80 and over
Bioprosthesis
Heart Valve Prosthesis Implantation
Ejection fraction
business.industry
Mitral valve replacement
Stroke Volume
EuroSCORE
Middle Aged
medicine.disease
Surgery
Treatment Outcome
medicine.anatomical_structure
England
Aortic Valve
Heart Valve Prosthesis
Multivariate Analysis
Mitral Valve
Female
Cardiology and Cardiovascular Medicine
business
Zdroj: Interactive CardioVascular and Thoracic Surgery. 14:575-579
ISSN: 1569-9285
1569-9293
DOI: 10.1093/icvts/ivs005
Popis: The aim of this study was to investigate the overall outcome of adult patients undergoing redo-mitral valve replacement (redo-MVR) at our institution. Forty-nine patients (24 males) underwent redo-MVR with either bioprosthetic (n = 24) or mechanical valves (n = 25) between January 2000 and 2010. Median age of patients was 63 years (range 21-80 years), and the mean additive EuroSCORE was 12 ± 4. Median time to re-operation was 8.2 ± 6.6 years for first time redo-MVR and 6.4 ± 5.6 years for second-time redo-MVR. Indications included prosthetic endocarditis (n = 22), para-prosthetic leak (n = 12), structural valve degeneration (n = 8), prosthetic valve thrombosis (n = 6) and malignancy (n = 1). The mean follow-up was 47.5 ± 37.0 months (range 0.1-112.3 months). In-hospital mortality was 12% (n = 6). Mean hospital stay was 17 ± 11 days (range 8-50 days). Actuarial survival at 1 and 5 years was 81 ± 5% and 72 ± 6%, respectively. Three patients required re-intervention: two for prosthetic valve endocarditis and one for para-prosthetic leak. Multivariate analysis showed that overall survival was associated with the LVEF < 50% (P < 0.001), concomitant AVR (P < 0.001) and urgent surgery (P = 0.03).
Databáze: OpenAIRE
Externí odkaz: